152 related articles for article (PubMed ID: 24346678)
21. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
[TBL] [Abstract][Full Text] [Related]
22. [Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B].
Calcagno JI; Augustovski F; Gadano A; Souto A; Yuan Y
Acta Gastroenterol Latinoam; 2008 Dec; 38(4):260-73. PubMed ID: 19157381
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
Yuan Y; Iloeje UH; Hay J; Saab S
J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
[TBL] [Abstract][Full Text] [Related]
24. Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis.
Wright AJ; Fishman JA; Chung RT
Am J Transplant; 2014 Mar; 14(3):629-34. PubMed ID: 24460820
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
Wu B; Shen J; Cheng H
BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
[TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of chronic hepatitis B treatments in Taiwan.
Lacey L; Chien RN; Chuang WL; Pwu RF
J Gastroenterol Hepatol; 2008 Apr; 23(4):571-9. PubMed ID: 18397486
[TBL] [Abstract][Full Text] [Related]
28. Telbivudine for the treatment of chronic hepatitis B infection.
Hartwell D; Jones J; Harris P; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
[TBL] [Abstract][Full Text] [Related]
29. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Arnold E; Yuan Y; Iloeje U; Cook G
Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
[TBL] [Abstract][Full Text] [Related]
31. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Dakin H; Bentley A; Dusheiko G
Value Health; 2010 Dec; 13(8):922-33. PubMed ID: 20825619
[TBL] [Abstract][Full Text] [Related]
32. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
33. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.
Yuan Y; Iloeje U; Li H; Hay J; Yao GB
Value Health; 2008 Mar; 11 Suppl 1():S11-22. PubMed ID: 18387054
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
Lacey LF; Gane E
J Viral Hepat; 2007 Nov; 14(11):751-66. PubMed ID: 17927611
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
36. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
[TBL] [Abstract][Full Text] [Related]
37. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
Dakin H; Sherman M; Fung S; Fidler C; Bentley A
Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
[TBL] [Abstract][Full Text] [Related]
39. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada.
He J; Bowen JM; Xie F; Goeree R
Value Health; 2012; 15(6):894-906. PubMed ID: 22999140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]